Search research articles
Contact Us
Filters
Showing results (81-90 of 93) with videos related to
Page
of 10
Sort By:
Journal of Hematology & Oncology
|
January 11, 2019
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial
Ilaria Saltarella, Fortunato Morabito, Nicola Giuliani, et al.
Critical Reviews in Oncology/Hematology
|
September 11, 2018
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis
Sara Bringhen, Massimo Offidani, Salvatore Palmieri, et al.
Haematologica
|
September 2, 2018
European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when
Jo Caers, Laurent Garderet, K Martin Kortüm, et al.
The Lancet. Haematology
|
May 13, 2022
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
Meletios A Dimopoulos, Paul G Richardson, Nizar J Bahlis, et al.
Blood
|
January 29, 2015
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report
Antonio Palumbo, Sara Bringhen, Maria-Victoria Mateos, et al.
European Journal of Haematology
|
September 8, 2021
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics
Paul G Richardson, Fredrik Schjesvold, Katja Weisel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 23, 2014
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival
Antonio Palumbo, Sara Bringhen, Alessandra Larocca, et al.
Haematologica
|
March 1, 2013
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials
Sara Bringhen, Maria Victoria Mateos, Sonja Zweegman, et al.
Haematologica
|
August 18, 2025
Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial
Sara Bringhen, Lorenzo Cani, Nicola Giuliani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 18, 2025
Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma
Martin F Kaiser, Pieter Sonneveld, David A Cairns, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 93) with videos related to
Sort By:
Page
of 10
Journal of Hematology & Oncology
|
January 11, 2019
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial
Ilaria Saltarella, Fortunato Morabito, Nicola Giuliani, et al.
Critical Reviews in Oncology/Hematology
|
September 11, 2018
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis
Sara Bringhen, Massimo Offidani, Salvatore Palmieri, et al.
Haematologica
|
September 2, 2018
European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when
Jo Caers, Laurent Garderet, K Martin Kortüm, et al.
The Lancet. Haematology
|
May 13, 2022
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
Meletios A Dimopoulos, Paul G Richardson, Nizar J Bahlis, et al.
Blood
|
January 29, 2015
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report
Antonio Palumbo, Sara Bringhen, Maria-Victoria Mateos, et al.
European Journal of Haematology
|
September 8, 2021
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics
Paul G Richardson, Fredrik Schjesvold, Katja Weisel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 23, 2014
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival
Antonio Palumbo, Sara Bringhen, Alessandra Larocca, et al.
Haematologica
|
March 1, 2013
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials
Sara Bringhen, Maria Victoria Mateos, Sonja Zweegman, et al.
Haematologica
|
August 18, 2025
Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial
Sara Bringhen, Lorenzo Cani, Nicola Giuliani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 18, 2025
Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma
Martin F Kaiser, Pieter Sonneveld, David A Cairns, et al.
Page
of 10